Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2012 / Cilt: 58 - Sayı: 2

Polymyalgia rheumatica in 21st century

21. Yüzyılda polimyaljiya romatika

Pages
143–150
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The experiences about using biologic agents are increasing in recent years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of elderly, characterised by pain and morning stiffness of the shoulder and pelvic girdle.
📊
Key Findings & Data:Although the ethiopathogenesis of PMR is unknown, environmental and genetic factors are suspected.
💡
Conclusion & Impact:The experiences about using biologic agents are increasing in recent years.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of elderly, characterised by pain and morning stiffness of the shoulder and pelvic girdle. Although the ethiopathogenesis of PMR is unknown, environmental and genetic factors are suspected. Despite the progress in imaging techniques achieved in recent years, there is no speific diagnostic test and the diagnosis is generally based on clinical features. The steroids are the main therapy for PRM. Thus, the dramatic response to steroid therapy has been used as a diagnostic criterion. However, there is lack of optimal intervention regarding initial dose, usage period and dose reduction. Moreover, relapses can be seen during the steroid therapy. Methotrexate can be used in case of unresponsiveness to steroids or aim to reduce daily steroid dose. The experiences about using biologic agents are increasing in recent years.

Özet

Polimyaljiya romatika (PMR), ileri yaş grubunda omuz ve pelvik kuşak ağrısı ve sabah tutukluğu ile karakterize inflamatuvar bir hastalıktır. Hastalığın etiyopatogenezi tam olarak bilinmemekle birlikte genetik ve çevresel faktörler suçlanmaktadır. Tanı için özgül bir test bulunmamakta, görüntüleme yöntemlerindeki gelişmelere rağmen tanı klinik bulgulara dayanmaktadır. Tedavisinde steroidler başlıca kullanılan ilaçlardır, hatta steroide verilen dramatik yanıt tanı kriteri olarak kullanılmıştır. Buna karşın steroidin başlangıç dozu, kullanım süresi, doz azaltılması konularında optimal bir yaklaşım söz konusu değildir. Dahası steroid tedavisi altında relapslar izlenebilmektedir. Steroidlerin etkisiz olduğu durumlarda veya steroidler kesilmek istendiğinde metotreksat kullanılabilmektedir. Son yıllarda biyolojik ajanların kullanılması ile ilgili deneyim artmaktadır.

🔖

Cite This Article

YAĞCI, İ. (2022). Polymyalgia rheumatica in 21st century. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 58 - Sayı: 2, 143–150. https://ajindex.com/articles/629342

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc 2006;81:1071-83
  2. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004;33:289-93
  3. Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995;38:369-73
  4. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J of Rheumatology 1995;34:261-4
  5. Okumura T, Tanno S, Ohhira M, Nozu T. The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan. Rheumatol Int. 2011 Mar 24. [Epub ahead of print] 6. Soriano A, Landolfi R, Manna R. Polymyalgia rheumatica in 2011. Best Pract Res Clin Rheumatol 2012;26:91-104
  6. Pamuk ON, Dönmez S, Karahan B, Pamuk GE, Cakir N. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data. Clin Exp Rheumatol 2009;27:830-3
  7. Aydeniz A, Altındağ O, Öğüt E, Gürsoy S. Late onset spondyloarthropathy mimicking polymyalgia rheumatica. Rheumatol Int 2012;32:1357-8
  8. Liozon E, Ouattara B, Rhaiem K, Ly K, Bezanahary H, Loustaud V et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol 2009;27(1 Suppl 52):89-94
  9. Bartolome MJ, Martínez-Taboda VM, Lopez-Hoyos M, Blanco R, Rodriguez-Valverde V. Familial aggregation of polymyalgia rheumatica and giant cell arteritis: genetic and T cell repertoire analysis. Clin Exp Rheumatol 2001;19:259-64
  10. Perfetto F, Moggi-Pignone A, Becucci A, Cantini F, Di Natale M, Livi R, et al. Seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 2005;64:1662-3
  11. Peris P. Polymyalgia rheumatica is not seasonal in pattern and is unrelated to parvovirus b19 infection. J Rheumatol 2003;30:2624-6
  12. Soriano A, Verrecchia E, Marinaro A, Giovinale M, Fonnesu C, Landolfi R, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus 2012;21:153-7
  13. Alvarez-Rodríguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R, et al. Circulating cytokines in active p